![](https://medcitynews.com/uploads/2021/07/GettyImages-1280895783-150x150.jpg)
Neumora Therapeutics
-
RayzeBio, Neumora Perk Up the IPO Market, Raising $561M for Clinical Trials
RayzeBio’s IPO will support pivotal testing of a targeted radiopharmaceutical for cancer patients who progress after treatment with Novartis’s Lutathera. Neumora will apply its IPO cash toward Phase 3 testing of a depression drug with a novel mechanism of action.
-
Q4 Was Digital Health’s Worst Quarter for Funding in 5 Years
Digital health’s investment slowdown is so severe that the fourth quarter of 2022 marked the lowest quarterly digital health funding total in the past five years, according to new report. Q4 was also the first quarter with no new unicorn births since 2018.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Allied with Amgen and backed by $500M, Neumora brings data science to brain drugs
Neumora Therapeutics unveiled $500 million in capital and a research partnership with Amgen. The startup analyzes neurological data to inform its drug research and development; President and Chief Operating Officer Lori Lyons-Williams said researching psychiatric drugs and neurodegenerative drugs within the same company allows brain insights from one area to inform the other.